AiCuris’ novel resistance breaking HIV compound AIC292 in phase I
Following oral administration the compound was generally well tolerated and the resulting pharmacokinetic profile was indicative of the potential for a once daily dosing regime. Commenting on the results Prof. Dr. Helga Rübsamen-Schaeff, CEO of AiCuris, stated ‘’We are very pleased about these results. Due to the chronic course of an HIV infection once daily dosing is one of the key prerequisites for a modern HIV drug in addition to good efficacy and tolerability.”
Like other compounds from AiCuris, AIC292 has a resistance-breaking profile. Prof. Rübsamen-Schaeff: “With this compound we have demonstrated once again the ability to generate innovative and attractive candidates for clinical development with our in house research in collaboration with external partners.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.